Team:SupBiotech-Paris/Bibliography

From 2009.igem.org

(Difference between revisions)
(→Title)
(→Ethics)
 
(9 intermediate revisions not shown)
Line 11: Line 11:
{|
{|
|- style="background: grey; color:white; text-align: center; font-weight:bold; "
|- style="background: grey; color:white; text-align: center; font-weight:bold; "
-
|width=120px height=40px|Chapitre
+
|width=120px height=40px|Chapter
|width=40px|Ref.
|width=40px|Ref.
-
|width=120px|Auteurs
+
|width=120px|Authors
-
|width=560px|Titre
+
|width=560px|Title
-
|width=70px|Lien
+
|width=70px|Year
|- style="background: white; text-align: center;"
|- style="background: white; text-align: center;"
Line 52: Line 52:
|XXXX
|XXXX
|}
|}
 +
 +
 +
<span style="float: right">[[Team:SupBiotech-Paris/Bibliography#drapeau|Back to top]]</span>
== Vectorization ==
== Vectorization ==
{|
{|
|- style="background: grey; color:white; text-align: center; font-weight:bold; "
|- style="background: grey; color:white; text-align: center; font-weight:bold; "
-
|width=120px height=40px|Chapitre
+
|width=120px height=40px|Chapter
|width=40px|Ref.
|width=40px|Ref.
-
|width=120px|Auteurs
+
|width=120px|Authors
-
|width=560px|Titre
+
|width=560px|Title
-
|width=70px|Lien
+
|width=70px|Year
|- style="background: #C0C0C0; text-align: center;"
|- style="background: #C0C0C0; text-align: center;"
Line 195: Line 198:
|2008
|2008
|}
|}
 +
 +
 +
<span style="float: right">[[Team:SupBiotech-Paris/Bibliography#drapeau|Back to top]]</span>
== Tissue Vector ==
== Tissue Vector ==
{|
{|
|- style="background: grey; color:white; text-align: center; font-weight:bold; "
|- style="background: grey; color:white; text-align: center; font-weight:bold; "
-
|width=120px height=40px|Chapitre
+
|width=120px height=40px|Chapter
|width=40px|Ref.
|width=40px|Ref.
-
|width=120px|Auteurs
+
|width=120px|Authors
-
|width=560px|Titre
+
|width=560px|Title
-
|width=70px|Lien
+
|width=70px|Year
|- style="background: white; text-align: center;"
|- style="background: white; text-align: center;"
Line 255: Line 261:
|2007
|2007
|}
|}
 +
 +
 +
<span style="float: right">[[Team:SupBiotech-Paris/Bibliography#drapeau|Back to top]]</span>
== Cell Vector ==
== Cell Vector ==
{|
{|
|- style="background: grey; color:white; text-align: center; font-weight:bold; "
|- style="background: grey; color:white; text-align: center; font-weight:bold; "
-
|width=120px height=40px|Chapitre
+
|width=120px height=40px|Chapter
|width=40px|Ref.
|width=40px|Ref.
-
|width=120px|Auteurs
+
|width=120px|Authors
-
|width=560px|Titre
+
|width=560px|Title
-
|width=70px|Lien
+
|width=70px|Year
|- style="background: #C0C0C0; text-align: center;"
|- style="background: #C0C0C0; text-align: center;"
Line 328: Line 337:
|1997
|1997
|}
|}
 +
 +
 +
<span style="float: right">[[Team:SupBiotech-Paris/Bibliography#drapeau|Back to top]]</span>
== Therapeutic Plasmide ==
== Therapeutic Plasmide ==
{|
{|
|- style="background: grey; color:white; text-align: center; font-weight:bold; "
|- style="background: grey; color:white; text-align: center; font-weight:bold; "
-
|width=120px height=40px|Chapitre
+
|width=120px height=40px|Chapter
|width=40px|Ref.
|width=40px|Ref.
-
|width=120px|Auteurs
+
|width=120px|Authors
-
|width=560px|Titre
+
|width=560px|Title
-
|width=70px|Lien
+
|width=70px|Year
|- style="background: white; text-align: center;"
|- style="background: white; text-align: center;"
Line 388: Line 400:
|}
|}
-
== Title ==
+
 
 +
<span style="float: right">[[Team:SupBiotech-Paris/Bibliography#drapeau|Back to top]]</span>
 +
 
 +
== Antitumor action ==
{|
{|
|- style="background: grey; color:white; text-align: center; font-weight:bold; "
|- style="background: grey; color:white; text-align: center; font-weight:bold; "
Line 395: Line 410:
|width=120px|Auteurs
|width=120px|Auteurs
|width=560px|Titre
|width=560px|Titre
-
|width=70px|Lien
+
|width=70px|Année
|- style="background: white; text-align: center;"
|- style="background: white; text-align: center;"
-
|height=40px|
+
|height=40px|Antitumor action
-
|[]
+
|[1]
-
|
+
|Chunlin Yang et al
-
|
+
|Adenovirus-mediated Wild-Type p53 Expression Induces Apoptosis and Suppresses Tumorigenesis of Prostatic Tumor Cells
-
|
+
|1995
|- style="background: #C0C0C0; text-align: center;"
|- style="background: #C0C0C0; text-align: center;"
-
|height=40px|
+
|height=40px|Antitumor action
-
|[]
+
|[2]
-
|
+
|Corrado Cirielli et al.
-
|
+
|Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of experimental intracranial human malignant glioma
-
|
+
|1999
|- style="background: white; text-align: center;"
|- style="background: white; text-align: center;"
-
|height=40px|
+
|height=40px|Antitumor action
-
|[]
+
|[3]
-
|
+
|Su-Ping Ren et al.
-
|
+
|Adenoviral-mediated transfer of human wild-type p53, GM-CSF and B7-1 genes results in growth suppression and autologous anti-tumor cytotoxicity of multiple myeloma cells in vitro
-
|
+
|2006
|- style="background: #C0C0C0; text-align: center;"
|- style="background: #C0C0C0; text-align: center;"
-
|height=40px|
+
|height=40px|Antitumor action
-
|[]
+
|[4]
-
|
+
|Zhao-hua Qiu et al
-
|
+
|Growth suppression and immunogenicity enhancement of Hep-2 or primary laryngeal cancer cells by adenovirus-mediated co-transfer of human wild-type p53, granulocyte-macrophage colony-stimulating factor and B7-1 genes
-
|
+
|2002
|- style="background: white; text-align: center;"
|- style="background: white; text-align: center;"
-
|height=40px|
+
|height=40px|Antitumor action
-
|[]
+
|[5]
-
|
+
|Zhao-hua Qiu et al.
-
|
+
|Co-transfer of human wild-type p53 and granulocyte-macrophage colony-stimulating factor genes via recombinant adenovirus induces apoptosis and enhances immunogenicity in laryngeal cancer cells
-
|
+
|2001
|- style="background: #C0C0C0; text-align: center;"
|- style="background: #C0C0C0; text-align: center;"
-
|height=40px|
+
|height=40px|Antitumor action
-
|[]
+
|[6]
-
|
+
|Markus Reiser et al.
-
|
+
|Induction of cell proliferation arrest and apoptosis in hepatoma cells through adenoviral-mediated transfer of p53 gene
-
|
+
|2000
|- style="background: white; text-align: center;"
|- style="background: white; text-align: center;"
-
|height=40px|
+
|height=40px|Antitumor action
-
|[]
+
|[7]
-
|
+
|Louis L. Pisters et al.
-
|
+
|Evidence That Transfer of Functional p53 Protein Results in Increased Apoptosis in Prostate Cancer
-
|
+
|2004
|- style="background: #C0C0C0; text-align: center;"
|- style="background: #C0C0C0; text-align: center;"
-
|height=40px|
+
|height=40px|Antitumor action
-
|[]
+
|[8]
-
|
+
|Susan C. Modesitt et al.
-
|
+
|In Vitro and in Vivo Adenovirus-mediated p53 and p16 Tumor Suppressor Therapy in Ovarian Cancer
-
|
+
|2001
|- style="background: white; text-align: center;"
|- style="background: white; text-align: center;"
-
|height=40px|
+
|height=40px|Antitumor action
-
|[]
+
|[9]
-
|
+
|Yong-song GUAN et al.
-
|
+
|Adenovirus-mediated wild-type p53 gene transfer in combination with bronchial arterial infusion for treatment of advanced non-small-cell lung cancer, one year follow-up
-
|
+
|2009
 +
|}
 +
 
 +
 
 +
<span style="float: right">[[Team:SupBiotech-Paris/Bibliography#drapeau|Back to top]]</span>
 +
 
 +
== Ethics ==
 +
{|
 +
|- style="background: grey; color:white; text-align: center; font-weight:bold; "
 +
|width=120px height=40px|Chapter
 +
|width=40px|Ref.
 +
|width=120px|Authors
 +
|width=560px|Title
 +
|width=70px|Year
 +
 
 +
|- style="background: white; text-align: center;"
 +
|height=40px|Ethics
 +
|[1]
 +
|Joël Rosnay
 +
|Biologie de synthèse: Enjeux et défis pour l’humanité
 +
|2004
|- style="background: #C0C0C0; text-align: center;"
|- style="background: #C0C0C0; text-align: center;"
-
|height=40px|
+
|height=40px|Ethics
-
|[]
+
|[2]
-
|
+
|Synbiosafe
-
|
+
|http://www.synbiosafe.eu/forum/
-
|
+
|2008
 +
|- style="background: white; text-align: center;"
 +
|height=40px|Ethics
 +
|[3]
 +
|Bernadette Bensaude Vincent, Dorothée Benoit-Browaeys
 +
|Petite typologie de la biologie synthétique et enjeux éthiques
 +
|2009
 +
 +
|- style="background: #C0C0C0; text-align: center;"
 +
|height=40px|Ethics
 +
|[4]
 +
|Anna Deplazes Æ Markus Huppenbauer
 +
|Synthetic organisms and living machines
 +
|2004
 +
 +
|- style="background: white; text-align: center;"
 +
|height=40px|Ethics
 +
|[5]
 +
|Schmidt M, Ganguli-Mitra A,and al.
 +
|A priority paper for the societal and ethical aspects of synthetic biology
 +
|2009
 +
 +
|- style="background: #C0C0C0; text-align: center;"
 +
|height=40px|Ethics
 +
|[6]
 +
|Parens E, Johnston J, Moses J.
 +
|Ethics. Do we need "synthetic bioethics"?
 +
|2009
 +
|}
 +
 +
 +
 +
<span style="float: right">[[Team:SupBiotech-Paris/Bibliography#drapeau|Back to top]]</span>
 +
 +
 +
<html>
 +
<div style="float: right; margin-right: -85px;">
 +
<a href="https://2009.igem.org/Team:SupBiotech-Paris/Ethic#drapeau" target="_self">
 +
<img title="Let's go to the next page !" style="width: 100px;" src="https://static.igem.org/mediawiki/2009/e/e9/Suivant.png";>
 +
</a></div>
 +
</html>
 +
 +
== Safety ==
 +
{|
 +
|- style="background: grey; color:white; text-align: center; font-weight:bold; "
 +
|width=120px height=40px|Chapter
 +
|width=40px|Ref.
 +
|width=120px|Authors
 +
|width=560px|Title
 +
|width=70px|Year
 +
 +
|- style="background: white; text-align: center;"
 +
|height=40px|Safety
 +
|[1]
 +
|Jonathan B. Tucker and al.
 +
|The Promise and Perils of Synthetic Biology
 +
|2006
 +
 +
|- style="background: #C0C0C0; text-align: center;"
 +
|height=40px|Safety
 +
|[2]
 +
|Synbiosafe
 +
|http://www.synbiosafe.eu/forum/
 +
|2008
 +
 +
|- style="background: white; text-align: center;"
 +
|height=40px|Safety
 +
|[3]
 +
|Vivagora
 +
|http://www.vivagora.org/IMG/pdf/CR-biosynth011009.pdf
 +
|2009
 +
 +
|- style="background: #C0C0C0; text-align: center;"
 +
|height=40px|Safety
 +
|[4]
 +
|New Atlantis
 +
|http://www.thenewatlantis.com/publications/life-from-scratch
 +
|2004
|}
|}

Latest revision as of 01:53, 22 October 2009

framless


Contents

Therapies

Chapter Ref. Authors Title Year
Current Therapies [1] Lechat P. Pharmacology 2006
Current Therapies [2] Bruguerolle B. Biological rhythms and medications: a source of variability often neglected in pharmacology 2008
Current Therapies [1] Kevin J. Scanlon and al. Cancer Gene Therapy: Challenges and Opportunities 2004
Gene Therapies [2] Gouze JN and al. A comparative study of the inhibitory effects of interleukin-1 receptor antagonist following administration as a recombinant protein or by gene transfer 2003
Gene Therapies [3] Centre for Genetics Education http://www.genetics.com.au/index.asp XXXX


Back to top

Vectorization

Chapter Ref. Authors Title Year
Vectorization [1] Couvreur P. L'encapsulation de médicament 2003
Vectorization [2] Andrieux K. and al. Nanotechnology and new drug 2003
Vectorization [3] Torchilin V.P. Recent Approaches to Intracellular Delivery of Drugs and DNA and Organelle Targeting 2006
Vectorization [4] Davis M.E. and al. Nanoparticle therapeutics: an emerging treatment modality for cancer 2008
Vectorization [5] Seow Y. and al. Biological Gene Delivery Vehicles: Beyond Viral Vectors 2009
Vectorization [6] Decroly E. Vectorology 2005
Vectorization [7] Robbins P.D. and al. Viral Vectors for Gene Therapy 1998
Vectorization [8] Wei M.Q. and al. Bacterial targeted tumour therapy-dawn of a new era 2008
Vectorization [9] Ryan R.M. and al. Use of bacteria in anti-cancer therapies 2005
Vectorization [10] Mehnert Solid lipid nanoparticles: Production, characterization and applications 2001
Vectorization [11] Lasic D.D. Liposomes in gene therapy 1996
Vectorization [12] Lutten J. and al. Biodegradable polymers as non-viral carriers for plasmid DNA delivery 2008
Vectorization [13] Jiskoot W. and al. Immunological Risk of Injectable Drug Delivery Systems 2009
Vectorization [14] Head M. and al. Mechanism and computer simulation of immune complex formation, opsonization, and clearance 1996
Vectorization [15] Koide H. and al. Particle size-dependent triggering of accelerated blood clearance phenomenon 2008
Vectorization [16] Ishida T. and al. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: Effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes 2005
Vectorization [17] Wang XY and al. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes 2007
Vectorization [18] Tosi M.F. and al. Innate immune responses to infection 2005
Vectorization [19] Linkov I and al. Nanotoxicology and nanomedicine: making hard decisions 2008


Back to top

Tissue Vector

Chapter Ref. Authors Title Year
Tissue Vector [1] Ronald S. and al. Antimicrobial mechanisms of phagocytes and bacterial evasion strategies 2009
Tissue Vector [2] Clark B. Inderlied and al. The Mycobacterium avium Complex 1993
Tissue Vector [3] Nisheeth Agarwal and al. Cyclic AMP intoxication of macrophages by a Mycobacterium tuberculosis adenylate cyclase 2009
Tissue Vector [4] Hunter R.L. and al. Pathology of postprimary tuberculosis in humans and mice: contradiction of long-held beliefs 2007
Tissue Vector [5] Axelrod S and al. Delay of phagosome maturation by a mycobacterial lipid is reversed by nitric oxide 2008
Tissue Vector [6] Nicole N van der Wel and al. Subcellular localization of mycobacteria in tissues and detection of lipid antigens in organelles using cryo-techniques for light and electron microscopy 2005
Tissue Vector [7] Claudia Nobrega and al. The thymus as a target for mycobacterial infections 2007


Back to top

Cell Vector

Chapter Ref. Authors Title Year
Cell Vector [1] Harrison Echols and al. Genetic Map of Bacteriophage Lambda 1978
Cell Vector [2] Joseph Sambrook and al. Molecular Cloning: A Laboratory Manual (Third Edition) 2001
Cell Vector [3] Court DL and al. A New Look at Bacteriophage lambda Genetic Networks 2007
Cell Vector [4] Ortega ME and al. Bacteriophage Lambda gpNu1 and Escherichia coli IHF Proteins Cooperatively Bind and Bend Viral DNA: Implications for the Assembly of a Genome-Packaging Motor 2006
Cell Vector [5] Feiss M. and al. Bactériophage Lambda Terminase and the Mechanism of Viral DNA Packaging 2005
Cell Vector [6] Hang JQ and al. The Functional Asymmetry of cosN, the Nicking Site for Bacteriophage λ DNA Packaging, Is Dependent on the Terminase Binding Site, cosB 2001
Cell Vector [7] Becker A and al. Bacteriophage lambda DNA : The begginning of the End 1990
Cell Vector [8] Hochschild A and al. The bactériophage lambda cI protein finds an asymmetric solution 2009
Cell Vector [9] Phoebe L.Stewart1 and al. Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization 1997


Back to top

Therapeutic Plasmide

Chapter Ref. Authors Title Year
Therapeutic Plasmide [1] Ortega ME et al. Bacteriophage lambda gpNu1 and Escherichia coli IHF proteins cooperatively bind and bend viral DNA: implications for the assembly of a genome-packaging motor 2006
Therapeutic Plasmide [2] Joseph Sambrook and al. Molecular Cloning: A Laboratory Manual (Third Edition) 2001
Therapeutic Plasmide [3] Court DL and al. A New Look at Bacteriophage lambda Genetic Networks 2007
Therapeutic Plasmide [4] Feiss M. and al. Viral Genome Packaging Machines: Genetics, Structure and Mechanism 2005
Therapeutic Plasmide [5] Hang JQ and al. The Functional Asymmetry of cosN, the Nicking Site for Bacteriophage λ DNA Packaging, Is Dependent on the Terminase Binding Site, cosB 2001
Therapeutic Plasmide [6] Becker A and al. Bacteriophage lambda DNA : The begginning of the End 1990
Therapeutic Plasmide [7] Young et al. Effect of a DNA nuclear targeting sequence on gene transfer and expression of plasmids in the intact vasculature 2003


Back to top

Antitumor action

Chapitre Ref. Auteurs Titre Année
Antitumor action [1] Chunlin Yang et al Adenovirus-mediated Wild-Type p53 Expression Induces Apoptosis and Suppresses Tumorigenesis of Prostatic Tumor Cells 1995
Antitumor action [2] Corrado Cirielli et al. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of experimental intracranial human malignant glioma 1999
Antitumor action [3] Su-Ping Ren et al. Adenoviral-mediated transfer of human wild-type p53, GM-CSF and B7-1 genes results in growth suppression and autologous anti-tumor cytotoxicity of multiple myeloma cells in vitro 2006
Antitumor action [4] Zhao-hua Qiu et al Growth suppression and immunogenicity enhancement of Hep-2 or primary laryngeal cancer cells by adenovirus-mediated co-transfer of human wild-type p53, granulocyte-macrophage colony-stimulating factor and B7-1 genes 2002
Antitumor action [5] Zhao-hua Qiu et al. Co-transfer of human wild-type p53 and granulocyte-macrophage colony-stimulating factor genes via recombinant adenovirus induces apoptosis and enhances immunogenicity in laryngeal cancer cells 2001
Antitumor action [6] Markus Reiser et al. Induction of cell proliferation arrest and apoptosis in hepatoma cells through adenoviral-mediated transfer of p53 gene 2000
Antitumor action [7] Louis L. Pisters et al. Evidence That Transfer of Functional p53 Protein Results in Increased Apoptosis in Prostate Cancer 2004
Antitumor action [8] Susan C. Modesitt et al. In Vitro and in Vivo Adenovirus-mediated p53 and p16 Tumor Suppressor Therapy in Ovarian Cancer 2001
Antitumor action [9] Yong-song GUAN et al. Adenovirus-mediated wild-type p53 gene transfer in combination with bronchial arterial infusion for treatment of advanced non-small-cell lung cancer, one year follow-up 2009


Back to top

Ethics

Chapter Ref. Authors Title Year
Ethics [1] Joël Rosnay Biologie de synthèse: Enjeux et défis pour l’humanité 2004
Ethics [2] Synbiosafe http://www.synbiosafe.eu/forum/ 2008
Ethics [3] Bernadette Bensaude Vincent, Dorothée Benoit-Browaeys Petite typologie de la biologie synthétique et enjeux éthiques 2009
Ethics [4] Anna Deplazes Æ Markus Huppenbauer Synthetic organisms and living machines 2004
Ethics [5] Schmidt M, Ganguli-Mitra A,and al. A priority paper for the societal and ethical aspects of synthetic biology 2009
Ethics [6] Parens E, Johnston J, Moses J. Ethics. Do we need "synthetic bioethics"? 2009


Back to top


Safety

Chapter Ref. Authors Title Year
Safety [1] Jonathan B. Tucker and al. The Promise and Perils of Synthetic Biology 2006
Safety [2] Synbiosafe http://www.synbiosafe.eu/forum/ 2008
Safety [3] Vivagora http://www.vivagora.org/IMG/pdf/CR-biosynth011009.pdf 2009
Safety [4] New Atlantis http://www.thenewatlantis.com/publications/life-from-scratch 2004


Back to top


Retrieved from "http://2009.igem.org/Team:SupBiotech-Paris/Bibliography"